{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T12:04:03Z","timestamp":1790165043705,"version":"4.1.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2017,5,29]],"date-time":"2017-05-29T00:00:00Z","timestamp":1496016000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"name":"ONLUS Sant'Andrea"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1007\/s00262-017-2026-7","type":"journal-article","created":{"date-parts":[[2017,5,29]],"date-time":"2017-05-29T08:23:36Z","timestamp":1496046216000},"page":"1295-1306","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Peripheral blood T cell alterations in newly diagnosed diffuse large B cell lymphoma patients and their long-term dynamics upon rituximab-based chemoimmunotherapy"],"prefix":"10.1007","volume":"66","author":[{"given":"Simone","family":"Battella","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Christina","family":"Cox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaella","family":"La Scaleia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianna","family":"Di Napoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Di Landro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Porzia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lavinia","family":"Franchitti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Mainiero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Ruco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Monarca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Santoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1467-1417","authenticated-orcid":false,"given":"Gabriella","family":"Palmieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,5,29]]},"reference":[{"key":"2026_CR1","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.critrevonc.2012.12.009","volume":"87","author":"M Martelli","year":"2013","unstructured":"Martelli M, Ferreri AJ, Agostinelli C, Di Rocco A, Pfreundschuh M, Pileri SA (2013) Diffuse large B-cell lymphoma. Crit Rev Oncol Hematol 87:146\u2013171. doi:\n                        10.1016\/j.critrevonc.2012.12.009","journal-title":"Crit Rev Oncol Hematol"},{"key":"2026_CR2","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1182\/blood-2014-05-577189","volume":"125","author":"LH Sehn","year":"2015","unstructured":"Sehn LH, Gascoyne RD (2015) Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity. Blood 125:22\u201332. doi:\n                        10.1182\/blood-2014-05-577189","journal-title":"Blood"},{"key":"2026_CR3","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1056\/NEJMoa012914","volume":"346","author":"A Rosenwald","year":"2002","unstructured":"Rosenwald A, Wright G, Chan WC et al (2002) The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346:1937\u20131947. doi:\n                        10.1056\/NEJMoa012914","journal-title":"N Engl J Med"},{"key":"2026_CR4","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1093\/annonc\/mdu109","volume":"25","author":"R Vaidya","year":"2014","unstructured":"Vaidya R, Witzig TE (2014) Prognostic factors for diffuse large B-cell lymphoma in the R(X)CHOP era. Ann Oncol 25:2124\u20132133. doi:\n                        10.1093\/annonc\/mdu109","journal-title":"Ann Oncol"},{"key":"2026_CR5","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1038\/sj.leu.2402226","volume":"15","author":"N Selenko","year":"2001","unstructured":"Selenko N, Maidic O, Draxier S, Berer A, J\u00e4ger U, Knapp W, St\u00f6ckl J (2001) CD20 antibody (C2B8)-induced apoptosis of lymphoma cells promotes phagocytosis by dendritic cells and cross-priming of CD8+ cytotoxic T cells. Leukemia 15:1619\u20131626","journal-title":"Leukemia"},{"key":"2026_CR6","doi-asserted-by":"publisher","first-page":"3809","DOI":"10.1182\/blood-2008-10-185280","volume":"113","author":"SP Hilchey","year":"2009","unstructured":"Hilchey SP, Hyrien O, Mosmann TR, Livingstone AM, Friedberg JW, Young F, Fisher RI, Kelleher RJ Jr, Bankert RB, Bernstein SH (2009) Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a \u201cvaccinal effect\u201d of rituximab. Blood 113:3809\u20133812. doi:\n                        10.1182\/blood-2008-10-185280","journal-title":"Blood"},{"key":"2026_CR7","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1182\/blood-2009-10-248609","volume":"116","author":"R Ab\u00e8s","year":"2010","unstructured":"Ab\u00e8s R, G\u00e9liz\u00e9 E, Fridman WH, Teillaud JL (2010) Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response. Blood 116:926\u2013934. doi:\n                        10.1182\/blood-2009-10-248609","journal-title":"Blood"},{"key":"2026_CR8","doi-asserted-by":"publisher","first-page":"e955684","DOI":"10.4161\/21624011.2014.955684","volume":"3","author":"HA Michaud","year":"2014","unstructured":"Michaud HA, Eliaou JF, Lafont V, Bonnefoy N, Gros L (2014) Tumor antigen-targeting monoclonal antibody-based immunotherapy: orchestrating combined strategies for the development of long-term antitumor immunity. Oncoimmunology 3:e955684. doi:\n                        10.4161\/21624011.2014.955684","journal-title":"Oncoimmunology"},{"key":"2026_CR9","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/nrc3237","volume":"12","author":"M Vanneman","year":"2012","unstructured":"Vanneman M, Dranoff G (2012) Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer 12:237\u2013251. doi:\n                        10.1038\/nrc3237","journal-title":"Nat Rev Cancer"},{"key":"2026_CR10","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.ccell.2015","volume":"28","author":"L Galluzzi","year":"2015","unstructured":"Galluzzi L, Buqu\u00e9 A, Kepp O, Zitvogel L, Kroemer G (2015) Immunological effects of conventional chemotherapy and targeted anticancer agents. Cancer Cell 28:690\u2013714. doi:\n                        10.1016\/j.ccell.2015","journal-title":"Cancer Cell"},{"issue":"3","key":"2026_CR11","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1111\/j.1365-2249.2012.04658.x","volume":"170","author":"S Manzur","year":"2012","unstructured":"Manzur S, Cohen S, Haimovich J, Hollander N (2012) Enhanced therapeutic effect of B cell-depleting anti-CD20 antibodies upon combination with in situ dendritic cell vaccination in advanced lymphoma. Clin Exp Immunol 170(3):291\u2013299. doi:\n                        10.1111\/j.1365-2249.2012.04658.x","journal-title":"Clin Exp Immunol"},{"key":"2026_CR12","doi-asserted-by":"publisher","first-page":"e941740","DOI":"10.4161\/21624011.2014.941740","volume":"3","author":"R Houot","year":"2014","unstructured":"Houot R, Kohrt H (2014) CD137 stimulation enhances the vaccinal effect of anti-tumor antibodies. Oncoimmunology 3:e941740. doi:\n                        10.4161\/21624011.2014.941740","journal-title":"Oncoimmunology"},{"key":"2026_CR13","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.3109\/10428194.2016.1157874","volume":"57","author":"G Lipowska-Bhalla","year":"2016","unstructured":"Lipowska-Bhalla G, Fagnano E, Illidge TM, Cheadle EJ (2016) Improving therapeutic activity of anti-CD20 antibody therapy through immunomodulation in lymphoid malignancies. Leuk Lymphoma 57:1269\u20131280. doi:\n                        10.3109\/10428194.2016.1157874","journal-title":"Leuk Lymphoma"},{"key":"2026_CR14","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1111\/imr.12245","volume":"263","author":"MH Nelson","year":"2015","unstructured":"Nelson MH, Paulos CM (2015) Novel immunotherapies for hematologic malignancies. Immunol Rev 263:90\u2013105. doi:\n                        10.1111\/imr.12245","journal-title":"Immunol Rev"},{"key":"2026_CR15","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.semcancer.2015.07.004","volume":"34","author":"JG Taylor","year":"2015","unstructured":"Taylor JG, Gribben JG (2015) Microenvironment abnormalities and lymphomagenesis: immunological aspects. Semin Cancer Biol 34:36\u201345. doi:\n                        10.1016\/j.semcancer.2015.07.004","journal-title":"Semin Cancer Biol"},{"key":"2026_CR16","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.3109\/10428194.2015.1011640","volume":"56","author":"ZZ Yang","year":"2015","unstructured":"Yang ZZ, Liang AB, Ansell SM (2015) T-cell-mediated antitumor immunity in B-cell non-Hodgkin lymphoma: activation, suppression and exhaustion. Leuk Lymphoma 56:2498\u20132504. doi:\n                        10.3109\/10428194.2015.1011640","journal-title":"Leuk Lymphoma"},{"key":"2026_CR17","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1038\/nri1961","volume":"6","author":"GP Dunn","year":"2006","unstructured":"Dunn GP, Koebel CM, Schreiber RD (2006) Interferons, immunity and cancer immunoediting. Nat Rev Immunol 6:836\u2013848. doi:\n                        10.1038\/nri1961","journal-title":"Nat Rev Immunol"},{"key":"2026_CR18","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1038\/ncomms1239","volume":"2","author":"OA Haabeth","year":"2011","unstructured":"Haabeth OA, Lorvik KB, Hammarstr\u00f6m C, Donaldson IM, Haraldsen G, Bogen B, Corthay A (2011) Inflammation driven by tumour-specific Th1 cells protects against B-cell cancer. Nat Commun 2:240. doi:\n                        10.1038\/ncomms1239","journal-title":"Nat Commun"},{"key":"2026_CR19","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.1182\/blood-2011-12-398321","volume":"120","author":"ZC Ding","year":"2012","unstructured":"Ding ZC, Huang L, Blazar BR, Yagita H, Mellor AL, Munn DH, Zhou G (2012) Polyfunctional CD4+ T cells are essential for eradicating advanced B-cell lymphoma after chemotherapy. Blood 120:2229\u20132239. doi:\n                        10.1182\/blood-2011-12-398321","journal-title":"Blood"},{"key":"2026_CR20","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1111\/j.1365-2567.2011.03539.x","volume":"135","author":"CA Lindqvist","year":"2012","unstructured":"Lindqvist CA, Loskog AS (2012) T regulatory cells in B-cell malignancy\u2014tumour support or kiss of death? Immunology 135:255\u2013260. doi:\n                        10.1111\/j.1365-2567.2011.03539.x","journal-title":"Immunology"},{"key":"2026_CR21","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1146\/annurev-immunol-032414-112043","volume":"33","author":"SR Woo","year":"2015","unstructured":"Woo SR, Corrales L, Gajewski TF (2015) Innate immune recognition of cancer. Annu Rev Immunol 33:445\u2013474. doi:\n                        10.1146\/annurev-immunol-032414-112043","journal-title":"Annu Rev Immunol"},{"key":"2026_CR22","doi-asserted-by":"publisher","first-page":"125","DOI":"10.3324\/haematol.2013.088161","volume":"99","author":"T Tadmor","year":"2014","unstructured":"Tadmor T, Bari A, Sacchi S, Marcheselli L, Liardo EV, Avivi I, Benyamini N, Attias D, Pozzi S, Cox MC, Baldini L, Brugiatelli M, Federico M, Polliack A (2014) Monocyte count at diagnosis is a prognostic parameter in diffuse large B-cell lymphoma: results from a large multicenter study involving 1191 patients in the pre- and post-rituximab era. Haematologica 99:125\u20131230. doi:\n                        10.3324\/haematol.2013.088161","journal-title":"Haematologica"},{"key":"2026_CR23","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1182\/blood-2015-08-662783","volume":"128","author":"I Azzaoui","year":"2016","unstructured":"Azzaoui I, Uhel F, Rossille D, Pangault C, Dulong J, Le Priol J, Lamy T, Houot R, Le Gouill S, Cartron G, Godmer P, Bouabdallah K, Milpied N, Damaj G, Tarte K, Fest T, Roussel M (2016) T-cell defect in diffuse large B-cell lymphomas involves expansion of myeloid derived suppressor cells expressing IL-10, PD-L1 and S100A12. Blood 128:1081\u20131092. doi:\n                        10.1182\/blood-2015-08-662783","journal-title":"Blood"},{"key":"2026_CR24","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/j.cyto.2012.08.028","volume":"60","author":"B Charbonneau","year":"2012","unstructured":"Charbonneau B, Maurer MJ, Ansell SM, Slager SL, Fredericksen ZS, Ziesmer SC, Macon WR, Habermann TM, Witzig TE, Link BK, Cerhan JR, Novak AJ (2012) Pretreatment circulating serum cytokines associated with follicular and diffuse large B-cell lymphoma: a clinic-based case-control study. Cytokine 60:882\u2013889. doi:\n                        10.1016\/j.cyto.2012.08.028","journal-title":"Cytokine"},{"key":"2026_CR25","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1007\/s00277-005-1020-x","volume":"84","author":"LM Pedersen","year":"2005","unstructured":"Pedersen LM, Klausen TW, Davidsen UH, Johnsen HE (2005) Early changes in serum IL-6 and VEGF levels predict clinical outcome following first-line therapy in aggressive non-Hodgkin\u2019s lymphoma. Ann Hematol 84:510\u2013516. doi:\n                        10.1007\/s00277-005-1020-x","journal-title":"Ann Hematol"},{"key":"2026_CR26","doi-asserted-by":"publisher","first-page":"98","DOI":"10.3389\/fimmu.2012.00098","volume":"3","author":"C Galand","year":"2012","unstructured":"Galand C, Donnou S, Molina TJ, Fridman WH, Fisson S, Saut\u00e8s-Fridman C (2012) Influence of tumor location on the composition of immune infiltrate and its impact on patient survival lessons from DCBCL and animal models. Front Immunol 3:98. doi:\n                        10.3389\/fimmu.2012.00098","journal-title":"Front Immunol"},{"key":"2026_CR27","doi-asserted-by":"publisher","first-page":"e445","DOI":"10.1016\/S2352-3026(15)00150-7","volume":"2","author":"C Keane","year":"2015","unstructured":"Keane C, Vari F, Hertzberg M, Cao KA, Green MR, Han E, Seymour JF, Hicks RJ, Gill D, Crooks P, Gould C, Jones K, Griffiths LR, Talaulikar D, Jain S, Tobin J, Gandhi MK (2015) Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based study. Lancet Haematol 2:e445\u2013e455. doi:\n                        10.1016\/S2352-3026(15)00150-7","journal-title":"Lancet Haematol"},{"key":"2026_CR28","doi-asserted-by":"publisher","first-page":"7951","DOI":"10.1007\/s13277-014-2080-0","volume":"35","author":"T Xiao","year":"2014","unstructured":"Xiao T, Zhang L, Chen L, Liu G, Feng Z, Gao L (2014) Tim-3 expression is increased on peripheral T cells from diffuse large B cell lymphoma. Tumour Biol 35:7951\u20137956. doi:\n                        10.1007\/s13277-014-2080-0","journal-title":"Tumour Biol"},{"key":"2026_CR29","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1111\/ejh.12144","volume":"91","author":"M G\u0142owala-Kosi\u0144ska","year":"2013","unstructured":"G\u0142owala-Kosi\u0144ska M, Chwieduk A, Nieckula J, Sadu\u015b-Wojciechowska M, Grosicki S, Rusin A, Nowara E, Giebel S (2013) Association of circulating regulatory T cell number with the incidence and prognosis of diffuse large B-cell lymphoma. Eur J Haematol 91:122\u2013128. doi:\n                        10.1111\/ejh.12144","journal-title":"Eur J Haematol"},{"key":"2026_CR30","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1080\/10428190802226425","volume":"49","author":"MC Cox","year":"2008","unstructured":"Cox MC, Nofroni I, Ruco L, Amodeo R, Ferrari A, La Verde G, Cardelli P, Montefusco E, Conte E, Monarca B, Aloe-Spiriti MA (2008) Low absolute lymphocyte count is a poor prognostic factor in diffuse-large-B-cell-lymphoma. Leuk Lymphoma 49:1745\u20131751. doi:\n                        10.1080\/10428190802226425","journal-title":"Leuk Lymphoma"},{"key":"2026_CR31","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1038\/leu.2011.112","volume":"25","author":"RA Wilcox","year":"2011","unstructured":"Wilcox RA, Ristow K, Habermann TM, Inwards DJ, Micallef IN, Johnston PB, Colgan JP, Nowakowski GS, Ansell SM, Witzig TE, Markovic SN, Porrata L (2011) The absolute monocyte and lymphocyte prognostic score predicts survival and identifies high-risk patients in diffuse large-B-cell lymphoma. Leukemia 25:1502\u20131509. doi:\n                        10.1038\/leu.2011.112","journal-title":"Leukemia"},{"key":"2026_CR32","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.3109\/10428194.2012.690605","volume":"53","author":"LF Porrata","year":"2012","unstructured":"Porrata LF, Ristow K, Habermann TM, Ozsan N, Dogan A, Macon W, Colgan JP, Witzig TE, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Nowakowski GS, Thompson C, Markovic SN (2012) Absolute monocyte\/lymphocyte count prognostic score is independent of immunohistochemically determined cell of origin in predicting survival in diffuse large B-cell lymphoma. Leuk Lymphoma 53:2159\u20132165. doi:\n                        10.3109\/10428194.2012.690605","journal-title":"Leuk Lymphoma"},{"key":"2026_CR33","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.3109\/10428194.2015.1014367","volume":"56","author":"B Lin","year":"2015","unstructured":"Lin B, Chen C, Qian Y, Feng J (2015) Prognostic role of peripheral blood lymphocyte\/monocyte ratio at diagnosis in diffuse large B-cell lymphoma: a meta-analysis. Leuk Lymphoma 56:2563\u20132568. doi:\n                        10.3109\/10428194.2015.1014367","journal-title":"Leuk Lymphoma"},{"key":"2026_CR34","doi-asserted-by":"publisher","first-page":"2728","DOI":"10.3109\/10428194.2014.893313","volume":"55","author":"LF Porrata","year":"2014","unstructured":"Porrata LF, Ristow KM, Habermann TM, Witzig TE, Colgan JP, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Nowakowski G, Thompson CA, Markovic SN (2014) Peripheral blood absolute lymphocyte\/monocyte ratio during rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone treatment cycles predicts clinical outcomes in diffuse large B-cell lymphoma. Leuk Lymphoma 55:2728\u20132738. doi:\n                        10.3109\/10428194.2014.893313","journal-title":"Leuk Lymphoma"},{"key":"2026_CR35","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1038\/leu.2010.108","volume":"24","author":"LF Porrata","year":"2010","unstructured":"Porrata LF, Rsitow K, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Habermann TM, Witzig TE, Colgan JP, Nowakowski GS, Thompson CA, Markovic SN (2010) Lymphopenia assessed during routine follow-up after immunochemotherapy (R-CHOP) is a risk factor for predicting relapse in patients with diffuse large B-cell lymphoma. Leukemia 24:1343\u20131349. doi:\n                        10.1038\/leu.2010.108","journal-title":"Leukemia"},{"key":"2026_CR36","doi-asserted-by":"publisher","first-page":"e990773","DOI":"10.4161\/2162402X.2014.990773","volume":"4","author":"MC Cox","year":"2015","unstructured":"Cox MC, Battella S, La Scaleia R, Pelliccia S, Di Napoli A, Porzia A, Cecere F, Alma E, Zingoni A, Mainiero F, Ruco L, Monarca B, Santoni A, Palmieri G (2015) Tumor-associated and immunochemotherapy-dependent long-term alterations of the peripheral blood NK cell compartment in DLBCL patients. Oncoimmunology 4:e990773. doi:\n                        10.4161\/2162402X.2014.990773","journal-title":"Oncoimmunology"},{"key":"2026_CR37","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","volume":"103","author":"CP Hans","year":"2004","unstructured":"Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, M\u00fcller-Hermelink HK, Campo E, Braziel RM, Jaffe ES, Pan Z, Farinha P, Smith LM, Falini B, Banham AH, Rosenwald A, Staudt LM, Connors JM, Armitage JO, Chan WC (2004) Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103:275\u2013282. doi:\n                        10.1182\/blood-2003-05-1545","journal-title":"Blood"},{"key":"2026_CR38","doi-asserted-by":"crossref","first-page":"596","DOI":"10.7326\/0003-4819-102-5-596","volume":"102","author":"P Klimo","year":"1985","unstructured":"Klimo P, Connors JM (1985) MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. Ann Intern Med 102:596\u2013602","journal-title":"Ann Intern Med"},{"key":"2026_CR39","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME et al (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25:579\u2013586. doi:\n                        10.1200\/JCO.2006.09.2403","journal-title":"J Clin Oncol"},{"key":"2026_CR40","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1200\/JCO.2013.51.5866","volume":"32","author":"MJ Maurer","year":"2014","unstructured":"Maurer MJ, Ghesqui\u00e8res H, Jais JP, Witzig TE, Haioun C, Thompson CA, Delarue R, Micallef IN, Peyrade F, Macon WR, Jo Molina T, Ketterer N, Syrbu SI, Fitoussi O, Kurtin PJ, Allmer C, Nicolas-Virelizier E, Slager SL, Habermann TM, Link BK, Salles G, Tilly H, Cerhan JR (2014) Event-free survival at 24\u00a0months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy. J Clin Oncol 32:1066\u20131073. doi:\n                        10.1200\/JCO.2013.51.5866","journal-title":"J Clin Oncol"},{"key":"2026_CR41","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1023\/A:1008389119525","volume":"10","author":"LD Piro","year":"1999","unstructured":"Piro LD, White CA, Grillo-L\u00f3pez AJ, Janakiraman N, Saven A, Beck TM, Varns C, Shuey S, Czuczman M, Lynch JW, Kolitz JE, Jain V (1999) Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin\u2019s lymphoma. Ann Oncol 10:655\u2013661","journal-title":"Ann Oncol"},{"key":"2026_CR42","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1111\/j.1600-0609.2004.00234.x","volume":"72","author":"L Gergely","year":"2004","unstructured":"Gergely L, Aleksza M, V\u00e1r\u00f3czy L, Ponyi A, Sipka S, Ill\u00e9s A, Szegedi G (2004) Intracellular IL-4\/IFN-gamma producing peripheral T lymphocyte subsets in B cell non-Hodgkin\u2019s lymphoma patients. Eur J Haematol 72:336\u2013341. doi:\n                        10.1111\/j.1600-0609.2004.00234.x","journal-title":"Eur J Haematol"},{"key":"2026_CR43","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/j.leukres.2005.02.009","volume":"29","author":"D Atanackovic","year":"2005","unstructured":"Atanackovic D, Panse J, Schafhausen P, Faltz C, Bartels K, Boeters I, Hossfeld DK, Hegewisch-Becker S (2005) Peripheral T cells of patients with B cell non-Hodgkin\u2019s lymphoma show a shift in their memory status. Leuk Res 29:1019\u20131027. doi:\n                        10.1016\/j.leukres.2005.02.009","journal-title":"Leuk Res"},{"key":"2026_CR44","doi-asserted-by":"publisher","first-page":"78","DOI":"10.3324\/haematol.2010.028241","volume":"96","author":"K Ait-Tahar","year":"2011","unstructured":"Ait-Tahar K, Liggins AP, Collins GP, Campbell A, Barnardo M, Cabes M, Lawrie CH, Moir D, Hatton C, Banham AH, Pulford K (2011) CD4-positive T-helper cell responses to the PASD1 protein in patients with diffuse large B-cell lymphoma. Haematologica 96:78\u201386. doi:\n                        10.3324\/haematol.2010.028241","journal-title":"Haematologica"},{"key":"2026_CR45","doi-asserted-by":"publisher","first-page":"3701","DOI":"10.1182\/blood-2007-09-111948","volume":"111","author":"LT Lam","year":"2008","unstructured":"Lam LT, Wright G, Davis RE, Lenz G, Farinha P, Dang L, Chan JW, Rosenwald A, Gascoyne RD, Staudt LM (2008) Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma. Blood 111:3701\u20133713. doi:\n                        10.1182\/blood-2007-09-111948","journal-title":"Blood"},{"key":"2026_CR46","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1182\/blood-2011-10-388538","volume":"119","author":"M Gupta","year":"2012","unstructured":"Gupta M, Han JJ, Stenson M, Maurer M, Wellik L, Hu G, Ziesmer S, Dogan A, Witzig TE (2012) Elevated serum IL-10 levels in diffuse large B-cell lymphoma: a mechanism of aberrant JAK2 activation. Blood 119:2844\u20132853. doi:\n                        10.1182\/blood-2011-10-388538","journal-title":"Blood"},{"key":"2026_CR47","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1002\/ajh.23398","volume":"88","author":"C Keane","year":"2013","unstructured":"Keane C, Gill D, Vari F, Cross D, Griffiths L, Gandhi M (2013) CD4(+) tumor infiltrating lymphocytes are prognostic and independent of R-IPI in patients with DLBCL receiving R-CHOP chemo-immunotherapy. Am J Hematol 88:273\u2013276. doi:\n                        10.1002\/ajh.23398","journal-title":"Am J Hematol"},{"key":"2026_CR48","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.ccr.2011.11.006","volume":"20","author":"M Challa-Malladi","year":"2011","unstructured":"Challa-Malladi M, Lieu YK, Califano O, Holmes AB, Bhagat G, Murty VV, Dominguez-Sola D, Pasqualucci L, Dalla-Favera R (2011) Combined genetic inactivation of \u03b22-Microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma. Cancer Cell 20:728\u2013740. doi:\n                        10.1016\/j.ccr.2011.11.006","journal-title":"Cancer Cell"},{"key":"2026_CR49","doi-asserted-by":"publisher","first-page":"4232","DOI":"10.1158\/1078-0432.CCR-10-2660","volume":"17","author":"DJ Andorsky","year":"2011","unstructured":"Andorsky DJ, Yamada RE, Said J, Pinkus GS, Betting DJ, Timmerman JM (2011) Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells. Clin Cancer Res 17:4232\u20134244. doi:\n                        10.1158\/1078-0432.CCR-10-2660","journal-title":"Clin Cancer Res"},{"key":"2026_CR50","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1182\/blood-2015-02-62960","volume":"126","author":"J Kiyasu","year":"2015","unstructured":"Kiyasu J, Miyoshi H, Hirata A, Arakawa F, Ichikawa A, Niino D, Sugita Y, Yufu Y, Choi I, Abe Y, Uike N, Nagafuji K, Okamura T, Akashi K, Takayanagi R, Shiratsuchi M, Ohshima K (2015) Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma. Blood 126:2193\u20132201. doi:\n                        10.1182\/blood-2015-02-62960","journal-title":"Blood"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00262-017-2026-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-017-2026-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-017-2026-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,10,4]],"date-time":"2017-10-04T03:59:39Z","timestamp":1507089579000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00262-017-2026-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,29]]},"references-count":50,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["2026"],"URL":"https:\/\/doi.org\/10.1007\/s00262-017-2026-7","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,29]]}}}